Tesla is up before earnings this week, and Opendoor Technologies' stock rose on an investor's prediction of a turnaround
Opendoor Technologies rose over 25% after a social media boost by an investor.
Eric Jackson's post predicted a strong turnaround, boosting the stock.
Opendoor Technologies, Tesla, Block, Navitas Semiconductor, and Incannex Healthcare are the most talked-about US stocks ahead of a fresh trading week.
This is where they were trading premarket as of 7 a.m. ET Monday —and what's driving the moves.
1. Opendoor Technologies
The move: The real estate company jumped over 20% to $2.72 a share, having gained about 36% on Friday.
Why: Opendoor's surge has followed a social media post by investor and Carvana spotter Eric Jackson, who wrote that he predicted a strong turnaround for the online platform. The stock's retail trading activity is up 140% in the past 10 days, per stocks and ETF data provider VandaTrack.
2. Tesla
The move: Elon Musk's EV maker is up 1.4% to $334.29 per share, after rising about 3% on Friday.
Why: The company is set to report quarterly earnings on Wednesday. Tesla stock rose after the past two postings, despite weaker-than-expected results. This week's earnings will indicate the health of the EV manufacturer after Musk's return from his role at Doge.
3. Block
The move: The firm that operates Square and Cash App is up about 9% to $79.60 a share, bringing its increase to more than 15% in the past month.
Why: The jump came on the news that Block will be added to the S&P 500 on Wednesday, replacing energy company Hess Corporation.
4. Navitas Semiconductor
The move: Its stock is up 5.6% to $7.17 a share, extending its gain of 8.3% on Friday.
Why: The California-headquartered company has made several announcements regarding key innovations this year, including gains in GaN semiconductor production and the development of 800V HVDC architecture for AI data centers as part of a collaboration with Nvidia.
5. Incannex Healthcare
The move: Shares were up 44% before the opening bell to $0.88, following a leap of over 60% on Friday.
Why: The Nasdaq-listed company is due to release more data this month on its ongoing trials of an oral drug for sleep apnea patients.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
How SpaceX's rocket diplomacy backfired in the Bahamas
By Joey Roulette NASSAU, Bahamas (Reuters) -When SpaceX was negotiating a deal with the Bahamas last year to allow its Falcon 9 rocket boosters to land within the island nation's territory, Elon Musk's company offered a sweetener: complimentary Starlink internet terminals for the country's defense vessels, according to three people familiar with the matter. The rocket landing deal, unlocking a more efficient path to space for SpaceX's reusable Falcon 9, was then signed in February last year by Deputy Prime Minister Chester Cooper, who bypassed consultation with several other key government ministers, one of the sources and another person familiar with the talks said. Reuters could not determine the dollar value of the Starlink arrangement or the number of vessels outfitted with Starlink terminals. The Bahamian military, mostly a sea-faring force with a fleet of roughly a dozen vessels, did not respond to a request for comment. Reuters found no evidence that Cooper broke any laws or regulations in striking the deal with SpaceX, but the people said the quick approval created tension within the Bahamian government. By this April, two months after the first and only Falcon 9 booster landed off the nation's Exuma coast, the Bahamas announced it had put the landing agreement on hold. The government said publicly it wanted a post-launch investigation after the explosion in March of a different SpaceX rocket, Starship, whose mid-flight failure sent hundreds of pieces of debris washing ashore on Bahamian islands. But the suspension was the result of the blindsided officials' frustration as well, two of the people said. "While no toxic materials were detected and no significant environmental impact was reported, the incident prompted a reevaluation of our engagement with SpaceX," Cooper, also the country's tourism chief, told Reuters through a spokesperson. SpaceX did not respond to questions for comment. Cooper and the prime minister's office did not respond to questions about how the rocket landing deal was arranged. SpaceX's setbacks in the Bahamas – detailed in this story for the first time – offer a rare glimpse into its fragile diplomacy with foreign governments. As the company races to expand its dominant space business, it must navigate the geopolitical complexities of a high-stakes, global operation involving advanced satellites and orbital-class rockets – some prone to explosive failure – flying over or near sovereign territories. These political risks were laid bare last month when Mexican President Claudia Sheinbaum said her government was considering taking legal action against SpaceX over 'contamination' related to Starship launches from Starbase, the company's rocket site in Texas, 2 miles north of the Mexican border. Her comments came after a Starship rocket exploded into a giant fireball earlier this month on a test stand at Starbase. Responding to Sheinbaum on X, SpaceX said its teams have been hindered from recovering Starship debris that landed in Mexican territory. MISSION TO MARS SpaceX is pursuing aggressive global expansion as Musk, its CEO, has become a polarizing figure on the world stage, especially following high-profile clashes with several governments during his time advising President Donald Trump. More recently he has fallen out with Trump himself. Starlink, SpaceX's fast-growing satellite internet venture, is a central source of revenue funding Musk's vision to send human missions to Mars aboard Starship. But to scale globally, SpaceX must continue to win the trust of foreign governments with which it wishes to operate the service, as rivals from China and companies like Jeff Bezos' Amazon ramp up competing satellite networks. The company's talks with Bahamian officials show how Starlink is also seen as a key negotiating tool for SpaceX that can help advance other parts of its business. According to SpaceX's orbital calculations, the Falcon 9 rocket can carry heavier payloads and more satellites to space if its booster is allowed to land in Bahamian territory. Meanwhile, Starship's trajectory from Texas to orbit requires it to pass over Caribbean airspaces, exposing the region to potential debris if the rocket fails, as it has in all three of its test flights this year. SpaceX's deal with the Bahamas, the government said, also included a $1 million donation to the University of Bahamas, where the company pledged to conduct quarterly seminars on space and engineering topics. The company must pay a $100,000 fee per landing, pursuant to the country's space regulations it enacted in preparation for the SpaceX activities. While SpaceX made steep investments for an agreement prone to political entanglement, the Falcon 9 booster landings could resume later this summer, two Bahamian officials said. Holding things up is the government's examination of a SpaceX report on the booster landing's environmental impact, as well as talks among officials to amend the country's space reentry regulations to codify a better approval process and environmental review requirements, one of the sources said. Arana Pyfrom, assistant director at the Bahamas' Department of Environmental Planning and Protection, said SpaceX's presence in the country is "polarizing". Many Bahamians, he said, have voiced concerns to the government about their safety from Starship debris and pollution to the country's waters. "I have no strong dislike for the exploration of space, but I do have concerns about the sovereignty of my nation's airspace," Pyfrom said. "The Starship explosion just strengthened opposition to make sure we could answer all these questions." STARSHIP FAILURES ROCK ISLANDS Starship exploded about nine and a half minutes into flight on March 6 after launching from Texas, in what the company said was likely the result of an automatic self-destruct command triggered by an issue in its engine section. It was the second consecutive test failure after a similar mid-flight explosion in January rained debris on the Turks and Caicos Islands, a nearby British overseas territory. Matthew Bastian, a retired engineer from Canada, was anchored in his sailboat on vacation near Ragged Island, a remote island chain in southern Bahamas, just after sunset when he witnessed Starship's explosion. What he initially thought was a rising moon quickly became an expanding fireball that turned into a "large array of streaking comets." "My initial reaction was 'wow that is so cool,' then reality hit me – I could have a huge chunk of rocket debris crash down on me and sink my boat!" he said. "Fortunately that didn't happen, but one day it could happen to someone." Thousands of cruise ships, ferries, workboats, fishing boats, yachts and recreational sailboats ply the waters around Caribbean islands each year, maritime traffic that is crucial for the Bahamas tourism industry. Within days of the explosion, SpaceX dispatched staff and deployed helicopters and speedboats to swarm Ragged Island and nearby islands, using sonar to scan the seafloor for debris, four local residents and a government official told Reuters. On the surface, recovery crews hauled the wreckage from the water and transferred it onto a much larger SpaceX vessel, typically used to catch rocket fairings falling back from space, the people said. The SpaceX team included its vice president of launch, Kiko Dontchev, who emphasized in a news conference with local reporters that the rocket is entirely different from the Falcon 9 boosters that would land off the Exuma coast under SpaceX's agreement. Joe Darville, chairman of a local environmental organization called Save The Bays, was angered by the Starship debris, as well as what he described as a "deal done totally in secret" over the Falcon 9 agreement. As Bahamian waters become increasingly polluted and coral reefs shrink, he's unhappy with the lack of transparency in his government's dealings with SpaceX. "Something like that should have never been made without consultation of the people in the Bahamas," he said. Pyfrom, the official from the Bahamas' environmental agency, said the review of the SpaceX report and the approval process will show "where we fell short, and what we need to improve on." SpaceX, meanwhile, is forging ahead with Starship. Musk said earlier this month he expects the next Starship rocket to lift off within the next three weeks. Sign in to access your portfolio
Yahoo
6 minutes ago
- Yahoo
The 3 Things That Matter for CRISPR Therapeutics Now
Key Points CRISPR Therapeutics' gene-editing treatments are highly customized and shockingly expensive. The market is watching to see if the underlying science can be applied to treat many diseases. The company has plenty of money right now, but its expenses could grow quite a bit from here. 10 stocks we like better than CRISPR Therapeutics › Biotechnology outfit CRISPR Therapeutics (NASDAQ: CRSP) isn't a name on many investors' radar -- and understandably so. Its market capitalization is a mere $6 billion. The company remains in the red largely because it's barely got any revenue to speak of. It's not likely to swing to a profit in the immediate future, either. Still, if you've got room in your portfolio for a little more risk paired with above-average upside potential, this is a stock worth adding to your watchlist (if not your portfolio) with three key things in mind. But first things first. What's CRISPR Therapeutics? Although the company was founded back in 2013, most of its time since then has been spent refining the work first done by Jennifer Doudna, Ph.D., and co-founder Emmanuelle Charpentier, Ph.D., who jointly figured out how to "edit" defective genetic code in a strand of DNA. By using a protein called Cas9 to find and remove a damaged portion of a genetic sequence and then replace it using a gene-editing biotechnology based on clustered regularly interspaced short palindromic repeats -- or CRISPR -- medical science is now able to do what was once unthinkable. It's still early days for the science -- very early. In fact, the FDA only made its first-ever approval of a gene-editing therapy in December of 2023. That's Casgevy, for the treatment of sickle cell disease, which was approved in the U.K. only a month earlier. The thing is, Casgevy is CRISPR Therapeutics' treatment, underscoring how well developed this biotech outfit's science is, and perhaps indirectly underscoring the fact that many rival drug developers are still well behind. Casgevy isn't the company's proverbial big Kahuna, however -- it's merely proof that gene editing can be successfully done. The heavy hitters in CRISPR's developmental pipeline are CTX310 for the treatment of certain cardiovascular diseases, and CTX131 and CTX112, both of which are taking aim at cancer using the very same CRISPR science. Although all of these drugs still have years of developmental work ahead of them, again, the underlying gene-editing technology works. Its potential applications are enormous. That's why CRISPR has a dozen or so others in clinical or pre-clinical trials also underway at this time. Three things to watch As time marches on, though, this stock's backstory is evolving from one broadly driven by an idea to one that increasingly hinges on some very specific factors. To this end, here are the three things that matter the most to current and prospective CRISPR Therapeutics shareholders right now -- and for the foreseeable future -- since they'll either drive the stock higher or let it slide into a sell-off. 1. Insurers and patients' acceptance of CRISPR-based medicine's cost While the science of using CRISPR to repair faulty cells is exciting, it's not exactly cheap or easy. See, Casgevy isn't a pill or an injection. It requires a sample of a patient's own blood stem cells to create a completely customized therapy, which is then infused back into that patient after he or she has undergone chemotherapy. All of this care can only be done at one of CRISPR's 65 authorized treatment centers. Total cost? A little over $2 million per patient. That's pretty steep for any therapy, but particularly for sickle cell disease, which at least has a handful of more affordable treatment options. The cost of treating life-threatening cancer is less of a stumbling block, even for insurers that may occasionally see bills nearly this size for even the most conventional of oncology treatment regimens. The price tag of this and any other future CRISPR-based therapy, however, is likely to remain in this ballpark, where payers may well balk. 2. The ongoing development of CTX310 Again, while Casgevy is approved to treat sickle cell disease, it's really more of a proving ground for the other drugs in CRISPR Therapeutics' developmental pipeline. This, of course, includes CTX131 and CTX112, but the company itself is putting the spotlight on CTX310 as a treatment for ANGPTL3 (angiopoietin-like 3), which is often associated with poorly regulated cholesterol, lipids, and triglycerides. If the company can demonstrate its solution is at least as good as (if not better than) alternative cholesterol-fighting drugs, investors might continue to support this stock. This information is coming. The company posted encouraging early results of CTX310's phase 1 clinical trial late last month, and says it intends to offer more detailed data at a healthcare conference scheduled for later in the year. If it's compelling enough, it could tamp down worries over the high cost of any CRISPR-based treatment. 3. Liquidity Finally, you'll want to keep an eye on CRISPR Therapeutics' liquidity, or the amount of cash it has on hand to cover its operating costs while it continues to develop CTX310 at the same time it's looking to expand Casgevy's commercialization. As of the end of the first quarter, CRISPR was sitting on $1.86 billion in cash, which is a lot for a company of this size. It's working through this money pretty quickly, though, shelling out nearly $150 million in operating expenses in Q1 alone. That doesn't include a full quarter's worth of the sort of costs the phase 1 trial of CTX310 is incurring now, or any other trials it starts or expands in the foreseeable future. Continued revenue growth from Casgevy should seemingly help offset some of this spending, even if not all of it. Indeed, the analyst community expects CRISPR's top line to soar from less than $50 million this year to more than $400 million in 2027, even if these same analysts believe the company will still be well in the red then. A few years' worth of losses isn't exactly unusual for a young biotech start-up. CRISPR Therapeutics would still lack much-needed scale even after such growth, though. The money it needs to spend just to get any meaningful degree of traction from Casgevy or maintain its clinical trials could far exceed any conceivable amount of revenue the newly approved drug might produce in the foreseeable future. Don't confuse what CRSP stock is So what's the call? There isn't one -- not this time. Buying or avoiding a stake in CRISPR Therapeutics is entirely up to you, depending on your risk tolerances and your ability to manage such a holding. If you're strictly a buy-and-hold investor, there's probably not enough certainty here yet to latch onto for the long haul. And there may never be. If you've got a speculative side that can tolerate risk in exchange for hype-driven reward, though, you could make a decent bullish case. Just don't confuse the two, or muddy the waters by trying to be both. The last thing you want to do here is talk yourself into a long-term position that requires you to ignore obvious red flags like the three potential ones discussed above. Should you buy stock in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025 James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool has a disclosure policy. The 3 Things That Matter for CRISPR Therapeutics Now was originally published by The Motley Fool
Yahoo
6 minutes ago
- Yahoo
Corsair's Elgato Launches Facecam 4K; Groundbreaking Solution Mainstreams 4K60 Video
MILPITAS, Calif., July 29, 2025--(BUSINESS WIRE)--CORSAIR® (Nasdaq: CRSR) subsidiary Elgato, a global leader in content creator technology, today launched Facecam 4K, a groundbreaking studio webcam that brings DSLR-level 4K60 video to mainstream creators. Designed with a professional imaging pipeline, including a SONY STARVIS 2 sensor, advanced image processor, and Elgato's Camera Hub software, Facecam 4K delivers ultra-smooth, uncompressed Ultra HD footage with cinematic flexibility. It's also the first webcam to support 49-mm lens filters, enabling popular pro-style effects like starbursts and diffusion. Facecam 4K is available now, representing a major innovative leap in webcam technology, making broadcast-quality video and professional creative control more accessible than ever. With results rivaling many professional cameras, Facecam 4K proves that incredible video no longer requires a prohibitively expensive setup. Thi La, Chief Executive Officer of Corsair, said, "Facecam 4K is a great example of how Elgato continues to lead in creator technology, delivering pro-level 4K60 quality without the usual cost or complexity. As the creator economy evolves, we see opportunities to expand what a streaming webcam can do, especially through software, filters, and deeper app integrations. We're excited to give creators the tools they need to enhance their brand image, and this is just one step in our broader plan to drive further innovation." Customers can order Facecam 4K starting today on and at authorized retailers in CORSAIR's global network. Webpages Learn more about Facecam 4K: Get high-resolution product images: Get the Camera Hub app: About Elgato Elgato is a world leader in online audiovisual technology, empowering content creators and digital professionals to transform their ideas into immersive, impactful experiences. From award-winning cameras, microphones, and lighting to control surfaces, capture cards, and studio mounts, Elgato sets industry benchmarks that shape the status quo of digital storytelling. Backed by parent company CORSAIR (Nasdaq: CRSR), the brand leverages a strong global distribution network and consistent product innovation to deliver sustained growth. A trusted name in a rapidly expanding market, Elgato drives value for both creators and investors through its commitment to excellence and forward-thinking strategy. About Corsair Gaming Corsair (Nasdaq: CRSR) is a leading global developer and manufacturer of high-performance products and technology for gamers, content creators, and PC enthusiasts. From award-winning PC components and peripherals to premium streaming equipment and smart ambient lighting, Corsair delivers a full ecosystem of products that work together to enable everyone, from casual gamers to committed professionals, to perform at their very best. Corsair also sells products under its Fanatec brand, the leading end-to-end premium Sim Racing product line; Elgato brand, which provides premium studio equipment and accessories for content creators; SCUF Gaming brand, which builds custom-designed controllers for competitive gamers; Drop, the leading community-driven mechanical keyboard brand; and ORIGIN PC brand, a builder of custom gaming and workstation desktop PCs. Forward-Looking Statements This press release contains express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the refinancing supporting the Company's growth plan and providing it flexibility to act on growth investments. Forward-looking statements are based on our management's beliefs, as well as assumptions made by, and information currently available to them. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected. Factors which may cause actual results to differ materially from current expectations include, but are not limited to: the Company's limited operating history, which makes it difficult to forecast the Company's future results of operations; current macroeconomic conditions, including the impacts of high inflation and risk of recession, on demand for our products, consumer confidence and financial markets generally; changes in trade regulations, policies, and agreements and the imposition of tariffs that affect our products or operations, including potential new tariffs that may be imposed on U.S. imports and our ability to mitigate; the Company's ability to build and maintain the strength of the Company's brand among gaming and streaming enthusiasts and ability to continuously develop and successfully market new products and improvements to existing products; the introduction and success of new third-party high-performance computer hardware, particularly graphics processing units and central processing units as well as sophisticated new video games; fluctuations in operating results; the loss or inability to attract and retain key management; the impacts from geopolitical events and unrest; delays or disruptions at the Company or third-parties' manufacturing and distribution facilities; and the other factors described under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission ("SEC") and our subsequent filings with the SEC. All forward-looking statements reflect our beliefs and assumptions only as of the date of this press release. We undertake no obligation to update forward-looking statements to reflect future events or circumstances. View source version on Contacts Investor Relations Contact: David Pasqualeir@ 914-337-8801 Media Contact: Timothy Bibatbiba@ 203-428-3222 Error in retrieving data Sign in to access your portfolio Error in retrieving data
